Tatlican Semih, Eren Cemile, Eskioglu Fatma
Department of Dermatology, Ministry of Health Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey.
J Dermatolog Treat. 2009;20(4):198-202. doi: 10.1080/09546630802684692.
Pimecrolimus was found to be effective for the treatment of seborrheic dermatitis in several studies and its off-label use is increasing gradually.
This study was conducted to obtain more detailed information concerning the daily use of pimecrolimus in seborrheic dermatitis and it also aims to contribute to data for the future construction of guidelines.
A total of 52 patients with seborrheic dermatitis enrolled in the study. Pimecrolimus 1% cream was applied twice daily. The mean cure and remission times, detailed responses of each clinical finding and side effects were investigated.
The mean cure and mean remission times were 13.34 and 47.98 days, respectively. Disease severity improved by 50% in between the third and seventh days. Pruritus responded first to pimecrolimus. The drug was equally effective for erythema and scaling. The most frequent side effect was the burning-tingling sensation. After the seventh day of the study, there was no side effect.
Pimecrolimus applications for the treatment of seborrheic dermatitis provide a complete cure in a short period of time and a sustained symptom-free period with low and self-limited side effects.
在多项研究中发现吡美莫司对脂溢性皮炎的治疗有效，其超说明书用药正在逐渐增加。
本研究旨在获取有关吡美莫司治疗脂溢性皮炎日常使用的更详细信息，并为未来指南的制定提供数据。
共有52例脂溢性皮炎患者纳入本研究。每天两次外用1%吡美莫司乳膏。研究平均治愈时间、缓解时间、各项临床症状的具体反应及副作用。
平均治愈时间和平均缓解时间分别为13.34天和47.98天。在第3天至第7天之间，疾病严重程度改善了50%。瘙痒对吡美莫司反应最快。该药物对红斑和脱屑同样有效。最常见的副作用是烧灼样刺痛感。研究第7天后，未出现副作用。
吡美莫司用于治疗脂溢性皮炎可在短时间内实现完全治愈，并维持无症状期，副作用少且为自限性。
